Blue Matter Blog

Precision Medicine Part I: The Science Behind Molecular Testing
March 18, 2019

Since scientists first sequenced the human genome nearly 20 years ago, we have all been increasingly enthusiastic about the potential for precision medicine to better diagnose and treat diseases. In oncology, targeted therapies against specific mutations have already demonstrated this promise, though only in the relatively limited settings where these therapies exist and testing is …

Building a Winning Differentiation Strategy in Oncology: Maximizing the End-to-End Stakeholder Experience
March 7, 2019

Part Four in a Series on Oncology Product Commercialization As we’ve written before, oncology launches are occurring more frequently, largely due to a rapidly evolving understanding of disease biology and massive investments in oncology research and development.  As a result, many indications are becoming more complex and competitive, with a greater number of approved molecules …

Are You Happy at Work? – A Peek at Blue Matter’s Global Happiness Survey
February 18, 2019

On February 1, Blue Matter launched its first Global Happiness Survey.  This monthly survey asks Blue Matter team members around the world to rate their current levels of happiness.  Even though the global survey just got started, the idea of measuring team happiness has a lengthy history within the firm, starting as regional efforts in …

Helping in the Fight Against Lung Cancer: The Addario Lung Cancer Foundation
February 11, 2019

At Blue Matter, we love what we do.  The work is interesting, and we always feel like we’re learning something new. There’s also a sense that, in our own small way, we’re joining in the fight against some of the world’s worst diseases.  Our team members have a passion for the areas in which they …

A Framework for Successfully Launching & Commercializing Rare Disease Products
January 28, 2019

Regardless of the product, launching a new biopharmaceutical drug is a time-consuming, expensive, and complex undertaking.  It requires sound strategy, expert planning, and effective cross-functional coordination to get everything done right.  The analogy is certainly not new but launch really is akin to conducting a symphony orchestra, ensuring that all members play their parts correctly, …

Cell-Based Cancer Immunotherapies: Commercial Risk, Curative Reward, Part Two
January 21, 2019

Part Two of a Two-Part Series:  Commercial Opportunity, Challenges, and Outlook In Part One of this series, we provided an overview of how the immune system can fight cancer, as well as the reasons it can sometimes fail in the effort.  In addition, we explored an extremely interesting class of therapies that show great promise …

Cell-Based Cancer Immunotherapies: Commercial Risk, Curative Reward, Part One
January 18, 2019

Part One of a Two-Part Series:  How Cancer Immunity Works & Types of Cell-Based Immunotherapy Until recently, cancer treatments for advanced disease were palliative in nature, seeking to reduce tumor burden and prolong life.  Curing metastatic disease was not considered possible. But over the past few decades, a new class of cancer treatments has demonstrated curative …

The Complex Oncology Audience
December 13, 2018

Part Three in a Six-Part Series on Oncology Product Commercialization In Part One of this series, we outlined five commercial challenges in oncology that biopharma decision-makers must face.  Part Two dealt with the first of those challenges, the “constant state of launch” that now exists in oncology.  In this installment, we introduce the complex array …

The Disruptive Potential of Gene Therapy: When will it fully realize its commercial potential?
December 7, 2018

Gene therapy has made significant advances over the past few years.  However, those therapeutic advances have not been accompanied by spectacular commercial successes, at least not yet.  This raises a simple question: When will gene therapy fully realize its commercial potential? We explored that question with a distinguished panel on November 7, 2018 at the …

Dealing with the Constant State of Launch in Oncology
November 7, 2018

Part Two in a Six-Part Series on Oncology Product Commercialization In Part One, we mentioned that the launch frequency for oncology products has increased significantly over the last several years.  While this trend is seen in other therapeutic areas across the industry, we believe the combination of factors driving this in oncology are somewhat unique …